Article

Oxymorphone: a review

VIP Palliative Care Program Greater Los Angeles Healthcare, Division of Hematology/Oncology, UCLA School of Medicine, 11301 Wilshire 111-H, Los Angeles, CA, USA.
Supportive Care Cancer (Impact Factor: 2.5). 03/2006; 14(2):109-15. DOI: 10.1007/s00520-005-0917-1
Source: PubMed

ABSTRACT Oxymorphone (oxymorphone hydrochloride) (14-hydroxy-dihydromorphinone), a semisynthetic mu-opioid agonist, was first approved by the US Food and Drug Administration in 1959. Oxymorphone is considered a more potent opioid than its parent compound, morphine. Recently, an immediate-release and long-acting oral formulation of this drug was developed that makes oxymorphone a new option in treating moderate to severe pain. This article reviews the pharmacodynamics, pharmacology, and clinical efficacy for this new option in treating moderate to severe pain.

1 Follower
 · 
208 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for the quantitation of oxymorphone (OM) in human whole blood and liver. Sample preparation was done by solid-phase extraction, using deuterated OM as the internal standard. Separation was achieved using a Waters Aquity UPLC HSS T3 column. Analysis utilized positive electrospray ionization and multiple reaction monitoring. As part of the validation, studies were conducted to determine potential interference, selectivity, ion suppression/enhancement and carryover. Calibration model, limit of detection (LOD), lower limit of quantitation (LLOQ), precision and accuracy were also established. The linear range of the method was 2-500 ng/mL in blood and 5-500 ng/g in the liver. The LOD and LLOQ were 2 ng/mL for blood and 5 ng/g for the liver. Blood and/or liver specimens from 30 cases were analyzed. OM concentrations ranged from 23 to 554 ng/mL (, n = 26) in blood and 48 to 1740 ng/g (, n = 30) in the liver.
    Journal of analytical toxicology 08/2013; 37(8). DOI:10.1093/jat/bkt077 · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sodium and potassium triethylzincate were isolated by Wanklyn in 1858, and are corner stones in the history of organometallic chemistry. Crystallisation of organozincates from neat dialkylzinc, in the absence of a coordinating solvent, can be expected to result in assembly of supramolecular structures, rather than formation of discrete molecules in the crystalline state. This inspired us to reinvestigate Wanklyn’s classical compounds. Crystallisation of sodium triethylzincate from benzene led to metallation of benzene and the formation of diethylphenylzincate anions. The compound is a two-dimensional network where Na+ ions link the zincate anions by coordination to both ethyl- and phenyl groups. We have also, accidently, isolated crystals of the two-dimensional coordination network [K2(ZnEt2)4O]n, displaying a rare oxo-centred core with an octahedral oxide ion surrounded by four zinc atoms and two potassium atoms.
    Journal of Organometallic Chemistry 05/2011; 696(10):2269-2273. DOI:10.1016/j.jorganchem.2010.12.001 · 2.30 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveA major goal of palliative care is to provide comfort, and pain is one of the most common causes of treatable suffering in patients with advanced disease. Opioids are indispensable for pain management in palliative care and can usually be provided by the oral route, which is safe, effective, and of lowest cost in most cases. As patients near the end of life, however, the need for alternate routes of medication increases with up to 70% of patients requiring a nonoral route for opioid administration. In order to optimize patient care, it is imperative that clinicians understand existing available options of opioid administration and their respective advantages and disadvantages.Methods We performed a literature review to describe the most commonly used and available routes that can substitute for oral opioid therapy and to provide a summary of factors affecting choice of opioid for use in palliative care in terms of benefits, indications, cautions, and general considerations.ResultsClinical circumstances will largely dictate appropriateness of the route selected. When the oral route is unavailable, subcutaneous, intravenous, and enteral routes are preferred in the palliative care population. The evidence supporting sublingual, buccal, rectal, and transdermal gel routes is mixed.Conclusions This review is not designed to be a critical appraisal of the quality of current evidence; rather, it is a summation of that evidence and of current clinical practices regarding alternate routes of opioid administration. In doing so, the overarching goal of this review is to support more informed clinical decision making.
    Pain Medicine 08/2014; 15(7). DOI:10.1111/pme.12464 · 2.24 Impact Factor

Preview

Download
8 Downloads
Available from